Gene therapy · Gene replacement · developed by Krystal Biotech
KB105 is a replication-defective, non-integrating HSV-1 vector carrying the TGM1 gene, formulated as a topical gel. It is designed to deliver TGM1, which encodes transglutaminase 1, to the skin in autosomal recessive ichthyosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05735158 | Phase 2 | Autosomal Recessive Ichthyosis | Unknown | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autosomal Recessive Ichthyosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →